Analyst firms · Morgan Stanley · IMRX

Morgan Stanley IMRX price target and rating history

Immuneering Corporation (IMRX) · Health Care

Morgan Stanley rates Immuneering Corporation (IMRX) Underweight with a $14 price target, as of its latest action on Dec 13, 2024. It has published 4 rating actions on IMRX since August 2021, including 1 upgrade and 2 downgrades.

Current rating
Underweight
Price target
$14
Median target, all firms
Too few
Actions on IMRX
4

Morgan Stanley price target on IMRX

$39$22$520222023202420252026
Morgan Stanley price target on IMRX, each point a stated target, August 2021 to April 2023.

Every Morgan Stanley rating on IMRX

How other firms rate IMRX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$14Aug 6, 2026
Cantor FitzgeraldOverweight$17Jul 8, 2026

Questions about Morgan Stanley and IMRX

What is Morgan Stanley's price target for IMRX?
Morgan Stanley's latest stated price target for Immuneering Corporation (IMRX) is $14, from its action on Apr 19, 2023.
What is Morgan Stanley's rating on IMRX?
Morgan Stanley rates IMRX Underweight, a bearish rating, as of Dec 13, 2024.
When did Morgan Stanley last change its view on IMRX?
On Dec 13, 2024, Morgan Stanley downgrades to Underweight from Equal-Weight.

All Morgan Stanley ratingsIMRX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.